Skip to main content
. 2026 Jan 30;17:1714022. doi: 10.3389/fimmu.2026.1714022

Figure 5.

Flow cytometry analysis and cytotoxicity assays are shown. Panel A displays histograms for OVCAR8 and PA-1 cells, measuring ADAM17 and HER2 expression. Panel B presents line graphs and bar charts showing the viability and cytotoxicity of OVCAR8 and PA-1 cells over 72 hours. The experiments compare the effects of different treatments with NK cells, including IL-15, trastuzumab, and TAB16/15, indicating statistical significance between groups.

TAB16/15 mediated ADCC against ovarian tumor cell lines expressing ADAM17. (A) Human ovarian carcinoma cell line, OVCAR8 NLR, and human epithelial ovarian cancer cell line, PA-1 NLR were analyzed for their ADAM17 and HER2 expression levels by flow cytometry. Representative histograms plots y-axis = cell number. (B) Enriched NK cells were co-cultured with OVCAR8 NLR (top) or PA-1 NLR (bottom) cells at an E:T ratio of 2:1 for 72 hours in the presence of IL-15 (10 ng/ml) +/– trastuzumab (5 μg/ml) or TAB16/15 (8.25 nM). Cytotoxicity was assessed by IncuCyte live cell imaging. The percentage of OVCAR8-NLR or PA-1 NLR cells was double normalized to target cells alone. The percent cytotoxicity at 72 hours was quantified (right). Mean +/- SD, n = 6. *p<0.05; **p<0.01; ***p<0.001; ns, not significant. Statistical significance was determined by one-way ANOVA with a Tukey post hoc test.